Neumora Therapeutics Inc (NMRA) - News Archive

Rosen Law Firm Urges Neumora Therapeutics Inc. Investors to Act Before Crucial Litigation Deadline NEW YORK, February 22, 2025 Rosen Law Firm, a renowned global investor rights advocacy group, has issued an advisory to...

Neumora Therapeutics Inc. a biopharmaceutical company focused on transforming the treatment landscape for neurological diseases, has recently garnered attention following a significant leadership transition. Paul L. Ber...

: Neumora Therapeutics Inc. has recently released the findings from its KOASTAL-1 study, which evaluated the efficacy of Navacaprant as a treatment for Major Depressive Disorder (MDD). The study, however, did not meet i...

Neumora Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative treatments for brain diseases, has recently made significant progress in its mission. The company announced the initiatio...

Neumora Therapeutics, a renowned pharmaceutical company, has made significant strides towards developing innovative treatments for bipolar depression and schizophrenia. After a series of research success, the company re...

In an exciting development in the pharmaceutical sphere, Neumora Therapeutics, Inc. (Nasdaq: NMRA), a prominent clinical-stage biopharmaceutical company, has recently publicized its plans to participate in a series of l...

Neumora Therapeutics Initiates Promising Clinical Study for Schizophrenia Treatment with Novel M4 Muscarinic Receptor ModulatorNeumora Therapeutics, a renowned pharmaceutical company known for its innovative approaches...